Onset of action defined as the first time point after initiation of treatment when RYALTRISTM demonstrated a statistically significant change from baseline in instantaneous total nasal symptom score (iTNSS) compared with placebo. Onset of action was observed within 15 minutes following the first dose of RYALTRISTM. Following the initial dose, iTNSS improved over the first week and was sustained through 2 weeks of treatment.3
The 12-hour rTNSS was reported over the 14-day treatment period.3
*For adults and pediatric patients 12 years of age and older.
†Significant differences in iTNSS change from baseline between RYALTRISTM and placebo.
‡Adapted from Hampel FC, et al. Allergy Asthma Proc. 2019.1
§Average of AM and PM rTNSS for each day (maximum score=12) and averaged over the 2-week treatment period.
||Statistically significant difference (P<0.05) using a gatekeeping strategy.
¶Sustained based on taking the recommended 2 doses daily as prescribed.
#Adapted from Gross GN, et al. Ann Allergy Asthma Immunol. 2019.2
**Not commercially marketed least square (LS) means, 95% confidence intervals (CIs), and P values were based on the mixed model repeated measures model, adjusting for covariates that include treatment, site, baseline, 12-hour reflective total nasal symptom score, and study day as the within-patient effect.